Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
A total number of 4223 proposals were submitted in response to the EIC Accelerator pilot (SME Instrument) October 7th, 2020 cut-off (H2020-EIC-SMEINST-2-2020-07_10-2020).
Source: Funding and Tender Portal
2023-10-09
|
6 months ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
2023-09-27
|
6 months ago |
NCP Flanders survey still open until 13 October |
2023-08-21
|
8 months ago |
NCP Flanders survey: looking for your feedback |
2023-06-08
|
10 months ago |
Industry 5.0 Award 2023- open for submission |
2021-11-16
|
2 years ago |
HUBCAP: support for SMEs leveraging Model-based Design in Cyber Physical Systems |
2021-04-29
|
2 years ago |
Submitted proposals - Fast Track to Innovation (FTI) - H2020-EIC-FTI-2018-2020 |
2021-04-29
|
2 years ago |
Deadline postponed - EIC Horizon Prize for 'Fuel from the Sun: Artificial Photosynthe... |
2021-04-26
|
2 years ago |
Deadline postponed - EIC Accelerator Open 2021HORIZON-EIC-2021-ACCELERATOROPEN-01 |
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.